This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
The Firm is representing a number of Risperdal lawsuit clients in the Pennsylvania litigation who allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic drug.
New York, New York (PRWEB) July 03, 2014
Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) that allege the atypical antipsychotic medication caused gynecomastia (male breast growth) in men and boys continue to move forward in a mass tort proceeding underway in Pennsylvanias Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to an Order issued on July 3, 2014, the Court has granted Plaintiffs Motion to Amend the Master Long Form Complaint being used in the litigation. The Order further directs Plaintiffs to file a proposed Third Amended Master Long Form Complaint upon notice of the Court. (In Re: Risperdal Litigation, Case Number 100300296)
Our Firm is representing a number of Risperdal lawsuit clients in this proceeding, all of whom allegedly developed gynecomastia due to their use of this drug. We are pleased to see the proceeding moving forward, says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.
Risperdal Gynecomastia Allegations
Court documents indicate that some 600 Risperdal lawsuits are currently pending in the Pennsylvania litigation. Hundreds of these claims allege that the medication can stimulate the bodys production of a hormone called prolactin, which is associated with female breast development and lactation. In men and boys, elevated prolactin levels can lead to male breast development. The lawsuits further allege that Johnson & Johnson and its Janssen Pharmaceuticals unit were aware of the alleged association between Risperdal and gynecomastia, but concealed this knowledge from doctors and patients. The companies are also accused of improperly promoting the off-label use of Risperdal in children long before any pediatric indications were approved in 2006.
In November 2013, the U.S. Department of Justice announced that Johnson & Johnson and Janssen had agreed to pay $2.2 billion to resolve criminal and civil charges regarding the marketing of Risperdal and other drugs. According to court documents filed in the case, the Justice Department had charged that the company concealed side effects associated with the medication, including an association with elevated levels of prolactin, a hormone associated with breast development and lactation. Federal prosecutors had also alleged that the companies improperly marketed Risperdal for pediatric uses. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Alleged victims of Risperdal and gynecomastia may be entitled to pursue their own lawsuit against Johnson & Johnson and Janssen. To learn more about the possible association between Risperdal and male breast growth, please visit Bernstein Liebhard LLPs website. For a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York States contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firms fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiffs recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
For the original version on PRWeb visit: http://www.prweb.com/releases/risperdal-lawsuit/risperdal-gynecomastia/prweb11996044.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.